National Psoriasis Foundation clinical consensus on disease severity.

National Psoriasis Foundation clinical consensus on disease severity.

MedLine Citation:	PMID: 17310004 Owner: NLM Status: MEDLINE
Abstract/OtherAbstract:	OBJECTIVES: A task force of the National Psoriasis Foundation Medical Board was convened to evaluate the current severity criteria of mild, moderate, and severe psoriasis and to make recommendations concerning a 2-tiered categorization of severity based on current clinical practice and related to intent to treat. PARTICIPANTS: This volunteer task force, led by David M. Pariser, MD, included Jerry Bagel, MD, Joel M. Gelfand, MD, MSCE, Neil J. Korman, MD, PhD, Christopher T. Ritchlin, MD, Bruce E. Strober, MD, PhD, Abby S. Van Voorhees, MD, and Melodie Young, MSN, RN, ANP. Meetings were held by teleconference and were coordinated and funded by the National Psoriasis Foundation. EVIDENCE: This task force reviewed psoriasis severity criteria and other published psoriasis consensus statements. Current standards of care and expert opinion were used to inform the process. CONSENSUS PROCESS: Based on meetings of the task force and under the guidance of David M. Pariser, MD, a statement was drafted by Elizabeth J. Horn, PhD, presented to the task force, and reviewed and approved by the task force. This statement was then reviewed and approved by Robert E. Kalb, MD, Gerald G. Krueger, MD, and Alan Menter, MD. The National Psoriasis Foundation Medical Board reviewed and endorsed this statement by a majority vote on March 2, 2006, at the medical board meeting. CONCLUSIONS: This clinical consensus statement proposes a 2-tiered system for plaque psoriasis therapy that reflects more accurately than the current system how patients are treated in clinical practice. This statement, focused on plaque psoriasis, is intended to assist medical professionals and insurance payers in understanding these 2 categories of patients with psoriasis and choosing appropriate therapies for these patients.

Authors:	David M Pariser; Jerry Bagel; Joel M Gelfand; Neil J Korman; Christopher T Ritchlin; Bruce E Strober; Abby S Van Voorhees; Melodie Young; Sheila Rittenberg; Mark G Lebwohl; Elizabeth J Horn;
Related Documents :	1288304 - Expert psychiatric evidence in sexual misconduct cases before state medical boards. 2216554 - Orthopedic preparticipation screening examination. 2751784 - The medical education evaluation program of the state of ohio. 8431254 - Validity of nbme part i and part ii scores for selection of residents in orthopaedic su... 16705264 - An improved asynchronous brain interface: making use of the temporal history of the lf-... 7719804 - Toward a medical-concept representation language. the canon group.
Publication Detail:	Type: Journal Article; Practice Guideline; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Detail:	Title: Archives of dermatology Volume: 143 ISSN: 0003-987X ISO Abbreviation: Arch Dermatol Publication Date: 2007 Feb
Date Detail:	Created Date: 2007-02-20 Completed Date: 2007-03-16 Revised Date: 2008-03-17
Medline Journal Info:	Nlm Unique ID: 0372433 Medline TA: Arch Dermatol Country: United States
Other Details:	Languages: eng Pagination: 239-42 Citation Subset: AIM; IM
Affiliation:	Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA.
Export Citation:	APA/MLA Format Download EndNote Download BibTex
MeSH Terms
Descriptor/Qualifier:	Humans Needs Assessment Psoriasis / classification, pathology, psychology Quality of Life Severity of Illness Index
Grant Support
ID/Acronym/Agency:	K23AR051125-01/AR/NIAMS NIH HHS
Comments/Corrections
Comment In:	Arch Dermatol. 2007 Feb;143(2):270-2 [PMID: 17310016 ] Arch Dermatol. 2007 Feb;143(2):233-6 [PMID: 17310003 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document: Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic...
Next Document: APOE epsilon4 is associated with impaired verbal learning in patients with MS.